Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001011273 | SCV001171573 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-05-05 | criteria provided, single submitter | clinical testing | The p.E462* pathogenic mutation (also known as c.1384G>T), located in coding exon 4 of the PALB2 gene, results from a G to T substitution at nucleotide position 1384. This changes the amino acid from a glutamic acid to a stop codon within coding exon 4. This alteration was observed with an allele frequency of 1 in 7051 unselected breast cancer patients and with an allele frequency of 1 in 11241 female controls of Japanese ancestry. (Momozawa Y et al. Nat Commun, 2018 Oct;9:4083). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Cancer Genomics Group, |
RCV001030652 | SCV001193683 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2019-05-01 | criteria provided, single submitter | research | |
Leiden Open Variation Database | RCV001030221 | SCV001193096 | pathogenic | not provided | 2018-10-10 | no assertion criteria provided | curation | Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Yukihide Momozawa. |
Laboratory for Genotyping Development, |
RCV003160174 | SCV002758151 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |